2 In the news

4 Review Article
Ensuring universal access to insulin – the International Insulin Foundation position statement
G Gill, J Yudkin, H Keen, and D Beran

6 Review Article
Diabetic foot care and prevention in Senegal: adding an extra dimension to the Step-by-Step model
K Slootmaeckers, K Van Ackier, and M N Mbaye

8 Original Article
Exploring the literature of diabetes in Nigeria: a bibliometrics study
Y I Harande

12 Original Article
Cardiovascular risk factors in type 2 diabetic patients in Libreville, Gabon
A F Ovono, S Bekale, J Fernandez, B A Mbang, and E Ngou-Milama

15 Original Article
Glucose-lowering effects of Momordica charantia in healthy rats
D M Matheka, T B Kiama, F O Alkizon, and F Bukachi

20 Original Article
Importance of accurate food measurement and physical exercise on BMI and glycaemic control in obese type 2 diabetic patients
G T Fadupin and O A Akinola

23 Guidance for Authors

The cost of diabetes
Diabetes is an expensive condition, and in many countries patients have to self-fund their care for the rest of their life. This can represent up to 75% of average household income, and insulin particularly can be 40% of total cost individual diabetes costs. Some countries have government-funded care, but these costs are still high and difficult for Ministries of Health to afford. For example, in both Tanzania and Mozambique, diabetes treatment represents about 10% of total national health expenditure. With the increasing prevalence of diabetes, these costs and their burden need to be addressed.

The International Insulin Foundation (IIF) [www.access2insulin.org] is a small charity which for the past 8 years has been exploring barriers to accessing diabetes care. The IIF has carried out surveys in six countries and has found that many purchase medicines for diabetes that fail to provide optimal care at the lowest cost. The Position Statement of the IIF (included in this issue of the AJDM) uses a set of principles related to appropriate selection and purchase of medicines which parallel advice in the Essential Medicines List of the World Health Organization (WHO). Such selection and purchase should be done as cost-effectively as possible and adapted to appropriate WHO, international, and national guidance.

Data from WHO in 2008 showed that 40 countries still had some form of import duty on insulin, and in 18 instances this exceeding 5%. Other value-added taxes may also exist. This is a tax on the sick, and should be strongly discouraged. Health professionals have a responsibility to prescribe rationally. Insulin types need to be prescribed according to national affordability and availability, and starting insulin therapy in type 2 diabetes should be done only when appropriate. 'Rational' is not the same as 'rationing' – money saved by appropriate use of insulin and other diabetes treatments can be used to effectively treat more people. We hope that the IIF Position Statement may stimulate debate on the future financing of diabetes care in Africa and other resource-limited areas of the world.

David Beran, Project Coordinator, International Insulin Foundation, UK; and Prof John S Yudkin MD FRCP Chairman, International Insulin Foundation, Emeritus Professor of Medicine, University College London, UK